Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Net Income towards Common Stockholders (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Net Income towards Common Stockholders for 6 consecutive years, with -$5.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income towards Common Stockholders fell 106.42% to -$5.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$17.1 million, a 35.64% decrease, with the full-year FY2024 number at -$11.1 million, up 18.27% from a year prior.
  • Net Income towards Common Stockholders was -$5.4 million for Q3 2025 at Vivos Therapeutics, down from -$5.0 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.7 million in Q1 2023 to a low of -$7.4 million in Q4 2021.
  • A 5-year average of -$4.4 million and a median of -$4.3 million in 2023 define the central range for Net Income towards Common Stockholders.
  • Peak YoY movement for Net Income towards Common Stockholders: tumbled 164.3% in 2021, then soared 68.05% in 2023.
  • Vivos Therapeutics' Net Income towards Common Stockholders stood at -$7.4 million in 2021, then increased by 17.64% to -$6.1 million in 2022, then increased by 29.35% to -$4.3 million in 2023, then surged by 34.29% to -$2.8 million in 2024, then plummeted by 91.02% to -$5.4 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Net Income towards Common Stockholders are -$5.4 million (Q3 2025), -$5.0 million (Q2 2025), and -$3.9 million (Q1 2025).